Literatur
- 1
Alpert M A, Concannon M D, Mukerji B, Mukerji V.
Pharmacotherapy of chronic
pulmonal arterial hypertension: value and limitations.
Angiology.
1994;
45
667-676
755-760
- 2
Barst R J, Rubin L J, Long W A. et al .
A comparison of continuous intravenous
epoprostenol (prostacyclin) with conventional therapy for primary
pulmonary hypertension.
N Engl J Med.
1996;
334
296-301
- 3
Barst R J, Rubin L J, McGoon M, Caldwell E J, Long W A, Levy P S.
Survival in primary
pulmonary hypertension with long-term continuous intravenous prostacyclin.
Ann
Intern Med.
1994;
121
409-415
- 4
Domenighetti G M, Saglini V G.
Short- and
longterm hemodynamic effects of oral nifidipine in patients with
pulmonary hypertension secondary to COPD and fibrosis.
Chest.
1992;
102
708-714
- 5
Frank H, Gurtner H P. et al. .
Aminorex-induzierte, plexiforme pulmonale
Arteriopathie: 25 Jahre danach.
Z Kardiol.
1993;
82
568-572
- 6
Fuster V, Steele P M, Edwards W D, Gersh B J, McGoon M D, Frye R L.
Primary
pulmonary hypertension.
Circulation.
1984;
70
580-587
- 7
Higenbottam T W, Butt A Y, McMahon A, Westerbeck R, Sharples L.
Long-term
intravenous prostaglandin (epoprostenol or iloprost) for treatment
of severe pulmonary hypertension.
Heart.
1998;
80
151-155
- 8
Higenbottam T W, Spiegelhalter D, Scott J P. et al .
Prostacyclin (epoprostenol) and heart-lung
transplantation as treatments for severe pulmonary hypertension.
Br
Heart J.
1993;
70
366-370
- 9
Hirsh J, Fuster V.
Guide
to anticoagulation therapy. Part 2: Oral anticoagulants.
Circulation.
1994;
89
1469-1480
- 10
Höper M M, Schwarze M, Ehlerding S. et al .
Long-term treatment of primary pulmonary
hypertension with aerosolized iloprost, a prostacyclin analogue.
N
Engl J Med.
2000;
342
1866-1870
- 11
Humbert M, Sanchez O, Fartoukh M. et al .
Short-term and long-term epoprostenol (prostacyclin)
therapy in pulmonary hypertension secondary to connective tissue
diseases.
Eur Respir J.
1999;
13
1351-1356
- 12
Jahed M M.
Hämodynamische
Akuteffekte von intravenös verabreichtem Molsidomin bei
sekundärer pulmonaler Hypertonie und Rechtsherzinsuffizienz.
Med
Klein.
1994;
89
58-61
(Suppl 2)
- 13
Khamashta M A, Cuadrado M J. et al. .
The
management of thrombosis in the antiphospholipid-antibody syndrome.
N
Engl J Med.
1995;
332
993-997
- 14
Kneussl M P, Lang I M, Brenot F P.
Medical
management of primary pulmonary hypertension.
Eur Respir
J.
1996;
9
2401-2409
- 15
Köhler D, Criée C P, Rasche F.
Leitlinien
zur häuslichen Sauerstoff- und Heimbeatmungstherapie.
Pneumologie.
1996;
50
927-931
- 16
Matthys H, Würtemberger G.
Empfehlungen
zur Sauerstoff-Langzeit-Therapie bei schwerer chronischer Hypoxämie.
Pneumologie.
1993;
47
2-4
- 17
McLaughlin V V, Genthner D E. et al. .
Reduction
in pulmonary vascular resistance with long-term epoprostenol (prostacyclin)
therapy in primary pulmonary hypertension.
N Engl J Med.
1998;
338
273-277
- 18
Mikhail G, Gibbs J SR, Richardson M. et al .
An evaluation of nebulized prostacyclin
in patients with primary and secondary pulmonary hypertension.
Eur
Heart J.
1997;
18
1499-1504
- 19
Nagaya N, Uematsu M, Okano Y. et al .
Effect of orally active prostacyclin analoque
on survival of outpatients with primary pulmonary hypertension.
J
Am Coll Cardiol.
1999;
34
1188-1192
- 20
Nocturnal oxygen therapy
trial group .
Continuous or nocturnal oxygen therapy
in hypoxemmic chronic obstructive lung disease.
Ann Intern
Med.
1980;
93
391-398
- 21
Okano Y, Yoshioka T, Shimouchi A, Satoh T, Kuniada T.
Orally active prostacyclin
analoque in primary pulmonary hypertension.
Lancet.
1997;
349
1365
- 22
Olschewski H, Ghofrani A, Walmrath D. et al .
Inhaled prostacyclin and iloprost in severe
pulmonary hypertension secondary to lung fibrosis.
Am
J Respir Crit Care Med.
1999;
160
600-607
- 23
Olschewski H, Walmrath D, Schermuly R, Ghofrani A, Grimminger F, Seeger W.
Aerosolized prostacyclin
and iloprost in severe pulmonary hypertension.
Ann Intern
Med.
1996;
124
820-824
- 24
Rich S, Brundage B H.
Highdose
calcium channel-blocking therapy for primary pulmonary hypertension:
evidence for long-term reduction in pulmonary arterial pressure
and regression of right ventricular hypertrophy.
Circulation.
1987;
76
135-141
- 25
Rich S, Kaufmannn E, Levy P S.
The effect of
high-dose of calcium-channel blockers on survival in primary pulmonary
hypertension.
N Engl J Med.
1992;
327
76-81
- 26
Rich S, Seidlitz M, Dodlin E. et al .
The short-term
effects of digoxin in patients with right venticular dysfunction
from pulmonary hypertension.
Chest.
1998;
114
787-792
- 27 Rich S. World
Symposium on Primary Pulmonary Hypertension 1998: Executive Summary. http://www.who.int/ncd/cvd/pph.html
- 28
Robbins I M, Christman B W, Newman J H, Matlock R, Loyd J E.
A
survey of diagnostic practices and the use of epoprostenol in patients
with primary pulmonary hypertension.
Chest.
1998;
114
1269-1275
- 29
Rosenzweig E B, Kerstein D, Barst R J.
Long-term
prostacyclin for pulmonary hypertension with associated congenital
heart defects.
Circulation.
1999;
99
1858-1865
- 30
Rubin L J, Mendoza J, Hood M, Barst R J. et al. .
Treatment of primary pulmonary hypertension
with continuous intravenous prostacyclin (epoprostenol).
Ann
Intern Med.
1990;
112
485-491
- 31
Rubin L J.
Primary
pulmonary hypertension.
Chest.
1993;
104
236-250
- 32
Rubin L J.
Primary
pulmonary hypertension.
N Engl J Med.
1997;
336
111-117
- 33
Saadjian A, Philip-Joet F, Vestri R, Arnaud A.
Longterm treatment of chronic
obstructive lung disease by nifidepine: An 18 month hemodynamic
study.
Eur Respir J.
1988;
1
716-720
- 34
Schauer J.
Therapie
des Cor pulmonale.
Inn Med.
1993;
48
544-549
- 35
Stricker H, Domenighetti G, Fiori G, Mombelli G.
Substained improvement
of performance and hemodynamics with long-term aerolized prostacyclin
therapy in severe pulmonary hypertension.
Schweiz Med
Wochenschr.
1999;
129
923-927
- 36
Weitzenblum E. et al .
Medical treatment of pulmonary hypertension in
chronic lung disease.
Eur Respir J.
1994;
7
148-152
- 37
Zielinski J, Tibiasz M. et al .
Effect
of long-term oxygen therapy on pulmonary hemodynamics in COPD patients.
Chest.
1998;
113
65-70
1 Der Beitrag »Diagnostik der pulmonalen Hypertonie« ist
im vorherigen
Heft (Nr. 11) erschienen
Korrespondenz
Dr. med. Ralf Ewert
Deutsches Herzzentrum Berlin Abt. für
Herz-, Thorax- und Gefäßchirugie
Augustenburger Platz 1
13353 Berlin
Fax: 030/45932143
eMail: rewert@dhzb.de
